Latest Pegfilgrastim Stories
Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy THOUSAND OAKS, Calif., March
Company currently has two biosimilar applications (filgrastim [Neupogen(®)]) and pegfilgrastim [Neulasta(®)]) under active review by FDA. TORONTO, Feb.
Believed to be the First Company to Have a Biosimilar Filing Accepted for Review of Amgen's Neulasta® TORONTO, Dec.
Surveyed European Oncologists Expect to Use Future Biosimilar G-CSFs in a Greater Proportion of Eligible Patients than Biosimilar MAbs, According to Findings from Decision Resources Group BURLINGTON,
Multicenter trial led by St Jude Children's Research Hospital investigators may change neutropenia treatment for all childhood cancer patients.
DALLAS, February 16, 2010 /PRNewswire/ -- - ReportsandReports announce to have Pipeline/Commercial Insight: Supportive Care in Oncology - Innovation and market growth limited to bone metastases management and emerging supportive care challenges ( http://www.reportsandreports.com/market-reports/pipeline-commercial-insight-s upportive-care-in-oncology-innova/) Market Research Report in its store (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into...
LAKE FOREST, Ill., Sept. 30 /PRNewswire-FirstCall/ -- Hospira, Inc.
SAN CARLOS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will be hosting a conference call to discuss today's announcement of a new partnership for NKTR-118 and NKTR-119. The call will begin at 8:30 a.m. Eastern Time (ET)/5:30 a.m.